期刊文献+

冉冉升起的肺癌靶向治疗新星:MET exon14-skipping

The Rising Star of Lung Cancer Targeted Therapy:MET exon14- skipping
下载PDF
导出
摘要 2014年7月,美国癌症基因研究组(The CancerGenome Atlas,TCGA)在《Nature》上发布了230例可切除肺腺癌的包含DNA、mRNA、micro RNA水平的综合基因谱分析结果。通过对mRNA和DNA高通量测序结果及序列比对分析,发现约4%(10/230)肺腺癌因MET基因DNA水平第14外显子剪接区域(splice-sites)的突变导致MET第14外显子在mRNA水平出现部分或完全跳跃缺失(exon14.skipping)。
作者 刘学文
出处 《循证医学》 CSCD 2016年第2期68-69,共2页 The Journal of Evidence-Based Medicine
关键词 肺癌 靶向治疗 MET exon14-skipping lung cancer targeted therapy MET cxonl4- skipping
  • 相关文献

参考文献7

  • 1Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma [J]. Nature, 2014, 511(7511) :543-550.
  • 2Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping[J]. Cancer Discov, 2015,5 (8) : 842-849.
  • 3Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors [J]. Cancer Discov, 2015,5(8) :850-859.
  • 4Liu X, Jia Y, Stoopler MB, et al. Next-Generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations[J]. J Clin Oneol, 2016,34(8) : 794-802.
  • 5Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non- small- cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression[J]. J Clin Oncol, 2016, 34(7) :721- 730.
  • 6Camidge DR, Ou S-HI, Shapiro G, et al. Efficacy and safety of Crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 32 (15s) : abstr 8001.
  • 7Ma PC. MET receptor Juxtamembrane exon 14 alternative spliced variant: Novel cancer genomic predictive biomarker[J]. Cancer Discov, 2015,5 (8) : 802-805.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部